1-(4-bromophenyl)-3-(3-(trifluoromethyl)phenyl)urea | 195452-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-bromophenyl)-3-(3-(trifluoromethyl)phenyl)urea
• 英文别名: 1-(4-bromophenyl)-3-[3-(trifluoromethyl)phenyl]urea
• CAS: 195452-46-1
• 化学式: C₁₄H₁₀BrF₃N₂O
• 分子量: 359.145
• InChiKey: UGHQRHZRMDPJSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-bromophenyl)-3-(3-(trifluoromethyl)phenyl)urea 、 联硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium acetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  [EN] INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE
  [FR] INHIBITEUR DE DIACYLGLYCÉROL ACYLTRANSFÉRASE

  摘要：

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂合物和药学上可接受的多晶形态。该发明还涉及制备这些杂环化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明进一步提供了一种治疗这些疾病或紊乱的方法，通过向有需要的哺乳动物施用所述化合物或其药物组合物的治疗有效量。

  公开号：

  WO2011080718A1
• 作为产物：
  描述：

  4-溴苯胺 、 3-(三氟甲基)异氰酸苯酯 以 四氢呋喃 为溶剂， 以96%的产率得到1-(4-bromophenyl)-3-(3-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  [EN] INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE
  [FR] INHIBITEUR DE DIACYLGLYCÉROL ACYLTRANSFÉRASE

  摘要：

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂合物和药学上可接受的多晶形态。该发明还涉及制备这些杂环化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明进一步提供了一种治疗这些疾病或紊乱的方法，通过向有需要的哺乳动物施用所述化合物或其药物组合物的治疗有效量。

  公开号：

  WO2011080718A1

文献信息

• Phosphate transport inhibitors
  申请人：Jozefiak H. Thomas

  公开号：US20070021509A1

  公开（公告）日：2007-01-25

  Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar 1 —W—X—Y—Ar 2 ; or a pharmaceutically acceptable salt thereof. Ar 1 and Ar 2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.

  本发明涉及已被鉴定为磷酸盐转运抑制剂的化合物。其中许多化合物由结构式（I）表示：Ar1-W-X-Y-Ar2；或其药学上可接受的盐。其中，Ar1和Ar2独立地为取代或未取代的芳基团或可选取代的五元或六元非芳基杂环团与可选取代的单环芳基团融合。W和Y独立地为共价键或C1-C3取代或未取代的烷基链。X为含杂原子的官能团、芳基杂环团、取代的芳基杂环团、非芳基杂环团、取代的非芳基杂环团、烯烃基或取代的烯烃基。本发明还涉及治疗与高磷血症相关的疾病以及由磷酸盐转运功能介导的疾病的方法。该方法包括给予上述化合物之一的有效量。
• INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE
  申请人：Jadhav Ravindra Dnyandev

  公开号：US20120289505A1

  公开（公告）日：2012-11-15

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体；以及它们的药学上可接受的盐，药学上可接受的溶剂化合物和药学上可接受的多晶形态。本发明还涉及制造这些杂环化合物的方法以及含有它们的制药组合物。所述化合物及其制药组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，尤其是DGAT1。本发明还提供了一种通过向需要治疗的哺乳动物中给予所述化合物或其制药组合物的治疗方法来治疗这些疾病或紊乱的方法。
• Inhibitors of diacylglycerol acyl transferase
  申请人：Jadhav Ravindra Dnyandev

  公开号：US08748426B2

  公开（公告）日：2014-06-10

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of the compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂化合物和药学上可接受的多晶形。本发明还涉及制造这些杂环化合物的方法以及含有它们的制药组合物。这些化合物及其制药组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明还提供了一种通过向需要治疗的哺乳动物中给予化合物或其制药组合物的治疗有效量来治疗这些疾病或紊乱的方法。
• US8748426B2
  申请人：——

  公开号：US8748426B2

  公开（公告）日：2014-06-10
• [EN] INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE<br/>[FR] INHIBITEUR DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011080718A1

  公开（公告）日：2011-07-07

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂合物和药学上可接受的多晶形态。该发明还涉及制备这些杂环化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明进一步提供了一种治疗这些疾病或紊乱的方法，通过向有需要的哺乳动物施用所述化合物或其药物组合物的治疗有效量。